GO:0002276 basophil activation involved in immune response: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002276 describes the morphological and behavioral change of a basophil after exposure to cytokines, chemokines, soluble factors, or antigen bound by IgE on Fc-epsilonRI receptors, leading to initiation or perpetuation of an immune response.
• Basophil activation is a hallmark of type I hypersensitivity and is central to IgE-mediated allergic inflammation, including food allergy and chronic spontaneous urticaria.
• Fc-epsilonRI cross-linking triggers degranulation and release of histamine, proteases, and lipid mediators, which drive vasodilation, pruritus, and smooth muscle contraction.
• Type 2 cytokines such as IL-4, IL-13, and IL-33 amplify basophil activation and contribute to skin barrier dysfunction in atopic dermatitis.
• Key genes and proteins in basophil activation include FCER1A, MS4A2, IL4, IL13, IL33, ST2 (IL1RL1), TPSAB1, CMA1, and GATA2.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of basophil activation pathways for allergy and inflammatory disease research.
Description
Basophils are rare circulating granulocytes that play an essential role in immune surveillance and allergic inflammation. GO:0002276, basophil activation involved in immune response, captures the process by which basophils change their morphology and behavior after exposure to cytokines, chemokines, soluble factors, or antigen that they specifically bind via IgE bound to Fc-epsilonRI receptors, ultimately initiating or perpetuating an immune response. This term is a biological process annotation that links molecular triggers to cellular outcomes such as degranulation, cytokine secretion, and mediator release. Understanding GO:0002276 is critical because basophil activation is a central mechanism in type I hypersensitivity reactions, including food allergy, allergic rhinitis, and chronic spontaneous urticaria. In type I hypersensitivity, antigen cross-links IgE on the basophil surface, leading to rapid release of histamine and other mediators that produce vasodilation, pruritus, and bronchoconstriction. Basophils also contribute to type 2 inflammation by producing IL-4 and IL-13, which promote Th2 polarization and IgE class switching. Recent work has highlighted that basophil activation is not limited to acute allergy but also participates in chronic inflammatory skin diseases such as atopic dermatitis, where type 2 cytokines impair skin barrier function. Therefore, researchers studying basophil activation need robust experimental models to dissect the genetic and molecular control of this process.
basophil activation involved in immune response At A Glance
| GO ID | GO:0002276 |
|---|---|
| GO term | basophil activation involved in immune response |
| Ontology | biological_process |
| Synonym | basophil activation during immune response |
| Major function | Morphological and behavioral change of basophils after cytokine, chemokine, soluble factor, or IgE/Fc-epsilonRI-bound antigen exposure, leading to immune response initiation or perpetuation |
| Cellular context | Basophil granulocytes, mast cells, and allergic effector cells |
| Key receptors | Fc-epsilonRI (high-affinity IgE receptor), cytokine receptors such as IL-33 receptor ST2 |
| Key mediators | Histamine, leukotrienes, proteases, IL-4, IL-13 |
| Associated diseases | Food allergy, chronic spontaneous urticaria, atopic dermatitis, type I hypersensitivity |
What Is GO:0002276?
GO:0002276, basophil activation involved in immune response, is defined as a change in morphology and behavior of a basophil resulting from exposure to a cytokine, chemokine, soluble factor, or to an antigen which the basophil has specifically bound via IgE bound to Fc-epsilonRI receptors, leading to the initiation or perpetuation of an immune response. In simpler terms, it is the process by which basophils become activated and start contributing to immune reactions, especially allergic responses.
Why Is basophil activation involved in immune response Important in Cell Biology?
GO:0002276 is important because basophil activation is a decisive event in type I hypersensitivity and type 2 inflammatory diseases, and it represents a tractable target for therapeutic intervention. Basophils are the least abundant granulocytes but can rapidly release large amounts of histamine and lipid mediators upon Fc-epsilonRI cross-linking, producing the classic symptoms of immediate hypersensitivity. In food allergy, basophil activation tests are used clinically to assess IgE-mediated reactivity, and the process is directly linked to anaphylaxis risk. In chronic spontaneous urticaria, basophil activation and autoallergy contribute to persistent wheals and angioedema. Moreover, basophil-derived IL-4 and IL-13 amplify Th2 responses and exacerbate skin barrier dysfunction in atopic dermatitis. IL-33, released from epithelial cells, further potentiates basophil activation and cytokine secretion. Therefore, understanding the genetic and molecular regulation of GO:0002276 can inform the development of targeted therapies for allergic and inflammatory diseases.
• Basophil activation is a core mechanism of type I hypersensitivity reactions, including food allergy and anaphylaxis.
• Fc-epsilonRI cross-linking on basophils triggers degranulation and release of histamine, proteases, and lipid mediators.
• Basophils produce IL-4 and IL-13, which promote Th2 polarization and IgE production.
• IL-33 and its receptor ST2 amplify basophil activation in allergic inflammation.
• Basophil activation contributes to chronic spontaneous urticaria and angioedema.
• Type 2 inflammation in atopic dermatitis involves basophil activation and skin barrier dysfunction.
• Staphylococcus aureus can exacerbate inflammatory skin diseases through type 2 immune activation.
• Basophil activation tests are used in clinical research to diagnose IgE-mediated allergy.
• Genetic variants in FCER1A and MS4A2 influence basophil activation and allergy risk.
• CRISPR-based models enable functional dissection of basophil activation genes for drug discovery.
What Happens During basophil activation involved in immune response?
Antigen recognition and Fc-epsilonRI cross-linking
In simple terms: The basophil uses IgE antibodies on its surface to recognize allergens, and when allergens bind, the receptors cluster together.
Basophil activation begins when multivalent antigens bind to IgE molecules already attached to the high-affinity Fc-epsilonRI receptor on the basophil surface. This cross-linking of Fc-epsilonRI triggers receptor aggregation and initiates intracellular signaling. In type I hypersensitivity, this step is rapid and antigen-specific, leading to the release of preformed mediators. The Fc-epsilonRI complex includes the alpha chain (FCER1A) that binds IgE and the beta chain (MS4A2) that amplifies signaling.
Intracellular signaling and calcium mobilization
In simple terms: Cross-linking sends signals inside the cell that raise calcium levels, which is the trigger for releasing inflammatory substances.
Fc-epsilonRI cross-linking activates tyrosine kinases such as Lyn and Syk, leading to phosphorylation of adaptor proteins and activation of PLC-gamma. This results in inositol trisphosphate production and calcium mobilization from intracellular stores. Elevated intracellular calcium is essential for granule fusion and mediator release. Cytokines such as IL-33 can also enhance basophil activation through ST2 receptor signaling, further amplifying calcium flux and cytokine production.
Degranulation and release of preformed mediators
In simple terms: The basophil releases histamine and other stored chemicals that cause allergy symptoms.
Upon calcium influx, basophil granules fuse with the plasma membrane and release histamine, heparin, and serine proteases such as tryptase and chymase. Histamine causes vasodilation, increased vascular permeability, pruritus, and smooth muscle contraction, which are hallmarks of immediate hypersensitivity. This degranulation step is a defining feature of basophil activation involved in immune response and is measured in basophil activation tests.
Lipid mediator synthesis and cytokine secretion
In simple terms: Activated basophils also make new inflammatory molecules and cytokines that prolong the immune reaction.
Activated basophils synthesize leukotrienes such as LTC4 and release them to sustain inflammation. They also secrete type 2 cytokines including IL-4 and IL-13, which promote Th2 differentiation and IgE class switching. IL-33 further enhances basophil cytokine production, linking epithelial alarmins to basophil activation in atopic dermatitis and other type 2 diseases. This late-phase response perpetuates the immune reaction and contributes to chronic inflammation.
Amplification and perpetuation of the immune response
In simple terms: The activated basophil recruits other immune cells and keeps the allergic response going.
Basophil-derived mediators and cytokines recruit eosinophils, Th2 cells, and other immune cells to the site of inflammation. In chronic spontaneous urticaria, basophil activation and autoallergy contribute to persistent wheals and angioedema. Staphylococcus aureus can exacerbate type 2 inflammation in skin, further amplifying basophil activation. Thus, GO:0002276 encompasses both the initial activation and the downstream perpetuation of immune responses.
Key Genes Involved in GO:0002276 basophil activation involved in immune response
The following genes and proteins are central to basophil activation involved in immune response, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCER1A | High-affinity IgE receptor alpha chain; binds IgE and initiates Fc-epsilonRI signaling | Target for allergy diagnostics and anti-IgE therapies |
| MS4A2 | Fc-epsilonRI beta chain; amplifies receptor signaling | Genetic variants linked to allergy and basophil activation |
| IL4 | Type 2 cytokine produced by activated basophils; promotes Th2 polarization | Biomarker and therapeutic target in allergic inflammation |
| IL13 | Type 2 cytokine; enhances IgE production and barrier dysfunction | Key mediator in atopic dermatitis and asthma |
| IL33 | Epithelial alarmin that activates basophils via ST2 | Target in type 2 inflammation and atopic dermatitis |
| IL1RL1 | Encodes ST2, the IL-33 receptor; mediates basophil activation | Genetic studies in allergy and inflammatory diseases |
| TPSAB1 | Tryptase alpha/beta-1; basophil and mast cell protease | Marker of degranulation and allergic reactions |
| CMA1 | Chymase; mast cell and basophil protease | Mediator of tissue remodeling in allergy |
| GATA2 | Transcription factor essential for basophil and mast cell development | Regulates basophil lineage commitment |
| SYK | Tyrosine kinase downstream of Fc-epsilonRI | Signaling target for mast cell and basophil inhibition |
| LYN | Src-family kinase that initiates Fc-epsilonRI signaling | Modulates basophil activation threshold |
| PLCG1 | Phospholipase C gamma 1; generates IP3 and DAG for calcium flux | Central to degranulation signaling |
| HRH1 | Histamine receptor H1; mediates histamine effects on target tissues | Target of antihistamines in urticaria and allergy |
| HRH2 | Histamine receptor H2; modulates gastric and immune responses | Studied in basophil-mediated inflammation |
| IL3 | Cytokine that primes basophils and enhances activation | Used in basophil activation assays |
| CSF2 | GM-CSF; promotes basophil survival and cytokine production | Modulates chronic allergic inflammation |
| FCER1G | Fc-epsilonRI gamma chain; contains ITAM for signaling | Amplifies basophil activation |
How Is basophil activation involved in immune response Regulated?
Basophil activation involved in immune response is tightly regulated at multiple levels. Fc-epsilonRI signaling is controlled by kinases such as Lyn and Syk, and by phosphatases that set activation thresholds. Cytokines including IL-3 and GM-CSF prime basophils for enhanced responsiveness, while IL-33 amplifies activation through ST2. Transcription factors such as GATA2 regulate basophil development and gene expression. In chronic spontaneous urticaria, autoantibodies and autoallergens can drive persistent basophil activation, and therapeutic anti-IgE or antihistamines modulate this process. Type 2 cytokines IL-4 and IL-13 further regulate basophil function in inflammatory microenvironments.
basophil activation involved in immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCER1A | IgE-mediated food allergy and type I hypersensitivity | Knockout and point-mutation models in basophil cell lines |
| MS4A2 | Allergy susceptibility and basophil activation | Knock-in of risk variants in primary basophils |
| IL4 | Atopic dermatitis and Th2 inflammation | Overexpression and knockout in T cell and basophil co-culture |
| IL33 | Type 2 inflammation and skin barrier dysfunction | Knockout and knock-in in epithelial and basophil models |
| TPSAB1 | Anaphylaxis and mast cell/basophil degranulation | Point-mutation and knockout in granulocyte models |
IgE-mediated food allergy and anaphylaxis
Basophil activation is a central mechanism in IgE-mediated food allergy, where allergen cross-linking of Fc-epsilonRI triggers degranulation and release of histamine and other mediators. Basophil activation tests are used to assess clinical reactivity, and severe activation can lead to anaphylaxis. Genetic and functional studies of FCER1A and MS4A2 help explain inter-individual differences in allergy severity.
Chronic spontaneous urticaria and angioedema
In chronic spontaneous urticaria, basophil activation contributes to persistent wheals and angioedema through autoallergy and autoantibody-mediated Fc-epsilonRI cross-linking. Basophil activation markers are studied as biomarkers of disease activity and response to anti-IgE therapy. Targeting basophil activation pathways may offer therapeutic benefit in refractory urticaria.
Atopic dermatitis and type 2 skin inflammation
Type 2 inflammation in atopic dermatitis involves basophil activation and cytokine production that impair skin barrier function. IL-33 released from epithelial cells activates basophils and other type 2 cells, exacerbating inflammation. Staphylococcus aureus colonization can further amplify type 2 immune responses in the skin. Therefore, basophil activation is a potential target in atopic dermatitis research.
Immediate hypersensitivity reactions
Immediate hypersensitivity reactions are driven by basophil and mast cell activation, with rapid release of histamine and lipid mediators. These reactions can be local or systemic and are a major clinical concern in drug and food allergy. Understanding GO:0002276 helps in developing diagnostics and therapeutics for immediate hypersensitivity.
From basophil activation involved in immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FCER1A loss impair basophil degranulation? | CRISPR knockout in basophil-like cell lines |
| Do MS4A2 variants alter Fc-epsilonRI signaling? | Point-mutation knock-in in primary basophils |
| Can IL-33 enhance basophil cytokine production? | Overexpression of IL33 in epithelial cells co-cultured with basophils |
| What is the role of GATA2 in basophil development? | Knockout and tagged knock-in in hematopoietic stem cells |
| Does IL-4 secretion from basophils promote Th2 polarization? | Knock-in reporter for IL4 in basophil precursors |
| Can SYK inhibition block basophil activation? | Point-mutation of SYK kinase domain and pharmacological inhibition |
How to Study the basophil activation involved in immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Basophil activation test (BAT) | CD63/CD203c upregulation after allergen stimulation | Clinical diagnosis of food and drug allergy |
| Flow cytometry | Surface markers and intracellular cytokines | Phenotyping activated basophils |
| ELISA/multiplex | Histamine, leukotrienes, IL-4, IL-13 release | Quantifying mediator release |
| RNA-seq | Transcriptional changes during activation | Identifying gene signatures in allergy |
| Proteomics | Secreted and intracellular proteins | Discovering biomarkers of basophil activation |
| CRISPR knockout screening | Gene requirement for activation | Functional genomics of Fc-epsilonRI signaling |
| Calcium flux assay | Intracellular calcium mobilization | Measuring early signaling events |
| Western blot | Phosphorylation of SYK, PLCG1 | Validating signaling pathways |
Basophil activation tests (BAT)
Basophil activation tests measure surface markers such as CD63 and CD203c by flow cytometry after allergen stimulation, providing a functional readout of GO:0002276. These tests are used clinically to diagnose IgE-mediated allergy and to monitor treatment response.
Flow cytometry and mediator release assays
Flow cytometry can quantify basophil degranulation and cytokine production, while ELISA and multiplex assays measure histamine, leukotrienes, and cytokines in supernatants. These methods link basophil activation to downstream immune effects.
Transcriptomics and proteomics
RNA sequencing and proteomics of activated basophils reveal gene expression changes and secreted proteins that characterize GO:0002276. These approaches identify novel biomarkers and therapeutic targets in allergic diseases.
CRISPR screening and functional genomics
CRISPR knockout and activation screens in basophil-like cell lines can identify genes that regulate Fc-epsilonRI signaling and degranulation. Such screens are powerful for discovering new modulators of basophil activation.
How CRISPR Can Be Used to Study GO:0002276 basophil activation involved in immune response
Knockout
CRISPR knockout of FCER1A, MS4A2, or SYK in basophil-like cell lines can abolish Fc-epsilonRI signaling and degranulation, providing causal evidence for their role in GO:0002276. Knockout models are also used to test whether candidate genes are required for cytokine production.
Point Mutation
Point mutations in MS4A2 or FCER1A can mimic human risk variants and reveal how single amino acid changes alter receptor signaling and basophil activation. Such models are valuable for precision allergy research.
Knock-in
Knock-in of reporter genes such as IL4-GFP or CD63-luciferase allows real-time monitoring of basophil activation and cytokine secretion. Knock-in of human IL33 or ST2 variants can model type 2 inflammation in vivo.
Overexpression
Overexpression of IL33, IL4, or IL13 in epithelial or immune cells can drive basophil activation and type 2 inflammation in co-culture systems. Overexpression models help identify sufficiency of individual genes in GO:0002276.
How EDITGENE Supports basophil activation involved in immune response Research
Researchers studying basophil activation involved in immune response-related genes often need to determine whether a candidate gene is causally involved in Fc-epsilonRI signaling, degranulation, or cytokine production. EDITGENE provides CRISPR-based cell model services to enable such causal experiments with high efficiency and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for basophil activation involved in immune response research.
Frequently Asked Questions About basophil activation involved in immune response
What is basophil activation involved in immune response (GO:0002276)?
GO:0002276 is a biological process describing the morphological and behavioral change of a basophil after exposure to cytokines, chemokines, soluble factors, or antigen bound by IgE on Fc-epsilonRI receptors, leading to initiation or perpetuation of an immune response.
What genes are involved in basophil activation involved in immune response?
Key genes include FCER1A, MS4A2, IL4, IL13, IL33, IL1RL1 (ST2), TPSAB1, CMA1, GATA2, SYK, LYN, and PLCG1.
How does basophil activation cause allergy symptoms?
Fc-epsilonRI cross-linking triggers degranulation and release of histamine, leukotrienes, and proteases, which cause vasodilation, pruritus, and bronchoconstriction.
What is the role of IL-33 in basophil activation?
IL-33 is an epithelial alarmin that activates basophils via the ST2 receptor, enhancing cytokine production and type 2 inflammation.
How is basophil activation measured in the lab?
Basophil activation tests measure CD63 or CD203c upregulation by flow cytometry after allergen stimulation, and mediator release can be quantified by ELISA.
What diseases are linked to basophil activation?
IgE-mediated food allergy, chronic spontaneous urticaria, atopic dermatitis, and immediate hypersensitivity reactions are linked to basophil activation.
Can CRISPR be used to study basophil activation genes?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal studies of genes such as FCER1A, MS4A2, and SYK in basophil activation.
What is the Fc-epsilonRI receptor?
Fc-epsilonRI is the high-affinity IgE receptor on basophils and mast cells; its cross-linking by antigen-IgE complexes initiates basophil activation.
How does atopic dermatitis involve basophil activation?
Type 2 inflammation in atopic dermatitis involves basophil activation and IL-4/IL-13 production, which impair skin barrier function.
What experimental models are used for basophil activation research?
Common models include basophil-like cell lines, primary basophils, and CRISPR-engineered cells for knockout, knock-in, and overexpression studies.
Conclusion
GO:0002276, basophil activation involved in immune response, is a fundamental biological process that underlies type I hypersensitivity and type 2 inflammatory diseases. Its definition encompasses the morphological and behavioral changes of basophils after exposure to cytokines, chemokines, soluble factors, or IgE/Fc-epsilonRI-bound antigen, leading to immune response initiation or perpetuation. Key genes such as FCER1A, MS4A2, IL4, IL13, and IL33 are central to this process and represent promising targets for therapeutic intervention. CRISPR-based models provide powerful tools to dissect the genetic control of basophil activation and to accelerate the development of new treatments for allergic and inflammatory diseases.
References
- 1. Anvari S et al.. 2019. IgE-Mediated Food Allergy.. Clin Rev Allergy Immunol 57(2):244-260 PMID: 30370459
- 2. Beck LA et al.. 2022. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.. JID Innov 2(5):100131 PMID: 36059592
- 3. Cayrol C et al.. 2022. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine.. Cytokine 156:155891 PMID: 35640416
- 4. Abbas M et al.. 2026. Type I Hypersensitivity Reaction.. PMID: 32809396
- 5. Chen H et al.. 2022. Exploring the Role of Staphylococcus aureus in Inflammatory Diseases.. Toxins (Basel) 14(7) PMID: 35878202
- 6. Saini SS et al.. 2025. Pathogenesis of Chronic Spontaneous Urticaria With or Without Angioedema.. J Allergy Clin Immunol Pract 13(9):2221-2228 PMID: 40721160
- 7. Sabir S et al.. 2026. Physiology, Immune Response.. PMID: 30969623
- 8. Justiz Vaillant AA et al.. 2026. Immediate Hypersensitivity Reactions.. PMID: 30020687
